title: Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
abstract: OBJECTIVE
  Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction.
  
  
  METHODS
  A retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared.
  
  
  RESULTS
  A total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78-10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79-188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal.
  
  
  CONCLUSIONS
  Adding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal.
authors.affiliation: Department of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
authors.forename: Mahmoud M
authors.initials: MM
authors.lastname: Mosli
authors.affiliation: Department of Gastroenterology and Hepatology, Saad Specialist Hospital, Al-Khobar, Kingdom of Saudi Arabia.
authors.forename: Moaiad
authors.initials: M
authors.lastname: Elyas
mesh_terms: D000328:Adult; D050110:Bariatric Surgery / Q000295:instrumentation* / Q000379:methods; D015992:Body Mass Index; D003131:Combined Modality Therapy; D005260:Female; D015905:Gastric Balloon; D006801:Humans; D000069450:Liraglutide / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D009767:Obesity, Morbid / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000069450:Liraglutide